4-Cyclohexa-1,5-dien-1-ylmorpholine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 4-Cyclohexa-1,5-dien-1-ylmorpholine
• 英文别名: 4-cyclohexa-1,5-dien-1-ylmorpholine
• 化学式: C₁₀H₁₅NO
• 分子量: 165.23
• InChiKey: RIAMFIIUIAWACF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• METHOD FOR PRODUCING CARBONYL COMPOUND AND FLOW REACTION SYSTEM USED FOR PRODUCTION OF CARBONYL COMPOUND
  申请人：FUJIFILM Corporation

  公开号：EP4019493A1

  公开（公告）日：2022-06-29

  There are provided a method of producing a carbonyl compound by a flow type reaction, including introducing a triphosgene solution into a flow channel (I), bringing the triphosgene solution into contact with a solid catalyst immobilized in at least a part of the flow channel (I) to generate a phosgene solution while the triphosgene solution is flowing through the flow channel (I), joining the phosgene solution and an active hydrogen-containing compound solution that flows inside the flow channel (II), which are subsequently allowed to flow downstream inside a reaction flow channel to be reacted in a presence of a tertiary amine, and obtaining a carbonyl compound in a joining solution; and a flow type reaction system that is suitable for carrying out this production method.

  提供了一种通过流动型反应生产羰基化合物的方法，包括将三光气溶液引入流动通道（I），在三光气溶液流经流动通道（I）时，使三光气溶液与固定在流动通道（I）至少一部分中的固体催化剂接触，生成光气溶液、将光气溶液与流道 (II) 内的活性含氢化合物溶液汇合，然后让它们顺流进入反应流道，在叔胺存在下进行反应，并在汇合溶液中获得羰基化合物；以及适用于该生产方法的流动式反应系统。
• Organic electroluminescent device
  申请人：LG Display Co., Ltd.

  公开号：EP1437395B1

  公开（公告）日：2011-12-14
• [EN] MACROCYCLIC INDOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'INDOLE MACROCYCLIQUES
  申请人：BAYER AG

  公开号：WO2017198341A1

  公开（公告）日：2017-11-23

  The present invention relates to macrocyclic indole derivatives of general formula (I) : (I), in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.